Your browser doesn't support javascript.
Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients.
Diray-Arce, Joann; Fourati, Slim; Doni Jayavelu, Naresh; Patel, Ravi; Maguire, Cole; Chang, Ana C; Dandekar, Ravi; Qi, Jingjing; Lee, Brian H; van Zalm, Patrick; Schroeder, Andrew; Chen, Ernie; Konstorum, Anna; Brito, Anderson; Gygi, Jeremy P; Kho, Alvin; Chen, Jing; Pawar, Shrikant; Gonzalez-Reiche, Ana Silvia; Hoch, Annmarie; Milliren, Carly E; Overton, James A; Westendorf, Kerstin; Cairns, Charles B; Rouphael, Nadine; Bosinger, Steven E; Kim-Schulze, Seunghee; Krammer, Florian; Rosen, Lindsey; Grubaugh, Nathan D; van Bakel, Harm; Wilson, Michael; Rajan, Jayant; Steen, Hanno; Eckalbar, Walter; Cotsapas, Chris; Langelier, Charles R; Levy, Ofer; Altman, Matthew C; Maecker, Holden; Montgomery, Ruth R; Haddad, Elias K; Sekaly, Rafick P; Esserman, Denise; Ozonoff, Al; Becker, Patrice M; Augustine, Alison D; Guan, Leying; Peters, Bjoern; Kleinstein, Steven H.
  • Diray-Arce J; Clinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA; Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: joann.arce@childrens.harvard.edu.
  • Fourati S; Emory School of Medicine, Atlanta, GA 30322, USA.
  • Doni Jayavelu N; Benaroya Research Institute, University of Washington, Seattle, WA 98101, USA.
  • Patel R; University of California San Francisco, San Francisco, CA 94115, USA.
  • Maguire C; The University of Texas at Austin, Austin, TX 78712, USA.
  • Chang AC; Clinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA.
  • Dandekar R; University of California San Francisco, San Francisco, CA 94115, USA.
  • Qi J; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Lee BH; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • van Zalm P; Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Schroeder A; University of California San Francisco, San Francisco, CA 94115, USA.
  • Chen E; Yale School of Medicine, New Haven, CT 06510, USA.
  • Konstorum A; Yale School of Medicine, New Haven, CT 06510, USA.
  • Brito A; Yale School of Public Health, New Haven, CT 06510, USA.
  • Gygi JP; Yale School of Medicine, New Haven, CT 06510, USA.
  • Kho A; Clinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA.
  • Chen J; Clinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA; Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Pawar S; Yale School of Medicine, New Haven, CT 06510, USA.
  • Gonzalez-Reiche AS; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Hoch A; Clinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA; Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Milliren CE; Clinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA.
  • Overton JA; Knocean, Inc., Toronto, ON M6P 2T3, Canada.
  • Westendorf K; La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Cairns CB; Drexel University, Tower Health Hospital, Philadelphia, PA 19104, USA.
  • Rouphael N; Emory School of Medicine, Atlanta, GA 30322, USA.
  • Bosinger SE; Emory School of Medicine, Atlanta, GA 30322, USA.
  • Kim-Schulze S; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Krammer F; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Rosen L; National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20814, USA.
  • Grubaugh ND; Yale School of Public Health, New Haven, CT 06510, USA.
  • van Bakel H; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Wilson M; University of California San Francisco, San Francisco, CA 94115, USA.
  • Rajan J; University of California San Francisco, San Francisco, CA 94115, USA.
  • Steen H; Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Eckalbar W; University of California San Francisco, San Francisco, CA 94115, USA.
  • Cotsapas C; Yale School of Medicine, New Haven, CT 06510, USA; Broad Institute of MIT & Harvard, Cambridge, MA 02142, USA.
  • Langelier CR; University of California San Francisco, San Francisco, CA 94115, USA.
  • Levy O; Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT & Harvard, Cambridge, MA 02142, USA.
  • Altman MC; Benaroya Research Institute, University of Washington, Seattle, WA 98101, USA.
  • Maecker H; Stanford University School of Medicine, Palo Alto, CA 94305, USA.
  • Montgomery RR; Yale School of Medicine, New Haven, CT 06510, USA.
  • Haddad EK; Drexel University, Tower Health Hospital, Philadelphia, PA 19104, USA.
  • Sekaly RP; Emory School of Medicine, Atlanta, GA 30322, USA.
  • Esserman D; Yale School of Public Health, New Haven, CT 06510, USA.
  • Ozonoff A; Clinical and Data Coordinating Center, Boston Children's Hospital, Boston, MA 02115, USA; Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT & Harvard, Cambridge, MA 02142, USA.
  • Becker PM; National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20814, USA.
  • Augustine AD; National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20814, USA.
  • Guan L; Yale School of Public Health, New Haven, CT 06510, USA.
  • Peters B; La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Kleinstein SH; Yale School of Medicine, New Haven, CT 06510, USA. Electronic address: steven.kleinstein@yale.edu.
Cell Rep Med ; 4(6): 101079, 2023 06 20.
Article in English | MEDLINE | ID: covidwho-2322799
ABSTRACT
The IMPACC cohort, composed of >1,000 hospitalized COVID-19 participants, contains five illness trajectory groups (TGs) during acute infection (first 28 days), ranging from milder (TG1-3) to more severe disease course (TG4) and death (TG5). Here, we report deep immunophenotyping, profiling of >15,000 longitudinal blood and nasal samples from 540 participants of the IMPACC cohort, using 14 distinct assays. These unbiased analyses identify cellular and molecular signatures present within 72 h of hospital admission that distinguish moderate from severe and fatal COVID-19 disease. Importantly, cellular and molecular states also distinguish participants with more severe disease that recover or stabilize within 28 days from those that progress to fatal outcomes (TG4 vs. TG5). Furthermore, our longitudinal design reveals that these biologic states display distinct temporal patterns associated with clinical outcomes. Characterizing host immune responses in relation to heterogeneity in disease course may inform clinical prognosis and opportunities for intervention.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Cell Rep Med Year: 2023 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Cell Rep Med Year: 2023 Document Type: Article